NCT01157845已完成3 期
Use of the BreathID Methacetin Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Patients Awaiting Liver Transplantation
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 165
- 试验地点
- 8
- 主要终点
- Mortality From Liver Failure
研究概览
简要总结
The methacetin breath test (MBT) is a non-invasive liver function test which measures the ability of the liver to metabolize a tracer dose of a compound to carbon dioxide, which is exhaled. The study hypothesis is that measurement of the MBT will allow earlier detection of a decline in liver function in patients with cirrhosis who are awaiting liver transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Mortality From Liver Failure
时间窗: 1 year
Patient dies of liver-related causes within 1 year of study entry
次要结局
- Liver Transplantation(1 year)
研究者
研究点 (8)
Loading locations...
相似试验
终止
2 期
BreathID Multi-center HCV Liver Breath Test StudyHepatitis CNCT00350714Meridian Bioscience, Inc.75
已完成
不适用
Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic DecompensationChronic Liver DiseaseNCT02084160Meridian Bioscience, Inc.579
Unknown
2 期
¹³C-Methacetin Breath Test (MBT) Methodology StudyHealthy SubjectsChronic Liver DiseaseCirrhosisNCT01205074Hadassah Medical Organization
已完成
不适用
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14NASH - Nonalcoholic SteatohepatitisCirrhosisPortal HypertensionNCT03439189Meridian Bioscience, Inc.343
已完成
不适用
Assessing Portal Hypertension With Methacetin Breath TestPatients With Compensated Liver CirrhosisNCT02143778Meridian Bioscience, Inc.246